Drug discovery could be significantly accelerated thanks to a new high precision machine-learning model, developed by an international collaboration of researchers, including the University of Warwick.
The algorithm – partly devised by Dr James Kermode from Warwick’s School of Engineering – can accurately predict the interactions between a protein and a drug molecule based on a handful of reference experiments or simulations.
Using just a few training references, it can predict whether or not a candidate drug molecule will bind to a target protein with 99% accuracy.
This is equivalent to predicting with near-certainty the activity of hundreds of compounds after actually testing them – by running only a couple dozen tests. The new method could accelerate the screening of candidate molecules thousands of times over.
The algorithm can also tackle materials-science problems such as modelling the subtle properties of silicon surfaces, and promises to revolutionise materials and chemical modelling – giving insight into the nature of intermolecular forces.
The approach, developed by scientists at the University of Warwick, the École polytechnique fédérale de Lausanne’s Laboratory of Computational Science and Modelling, the University of Cambridge, the UK Science and Technology Facilities Council and the U.S. Naval Research Laboratory, can also identify which parts of the molecules are crucial for the interaction.
“This work is exciting because it provides a general-purpose machine learning approach that is applicable both to materials and molecules.
“The research is expected to lead to a significant increase in the accuracy and transferability of models used for drug design and to describe the mechanical properties of materials.”
The design of this algorithm, which combines local information from the neighbourhood of each atom in a structure, makes it applicable across many different classes of chemical, materials science, and biochemical problems.
The approach is remarkably successful in predicting the stability of organic molecules, as well as the subtle energy balance governing the silicon structures crucial for microelectronic applications, and does so at a tiny fraction of the computational effort involved in a quantum mechanical calculation.
The research illustrates how chemical and materials discovery is now benefitting from the Machine Learning and Artificial Intelligence approaches that already underlie technologies from self-driving cars to go-playing bots and automated medical diagnostics.
New algorithms allow us to predict the behaviour of new materials and molecules with great accuracy and little computational effort, saving time and money in the process.
The Latest on: Drug discovery with machine learning
- Top 6 AI-Powered Drug Discovery Tools In 2021on April 30, 2021 at 12:30 am
AI has a lot of potential to enhance and accelerate drug discovery — the process of identifying potential medicines. In January 2020, British start-up Exscientia and Japanese pharmaceutical firm ...
- Shionogi bags agreement for Inveniai’s AI drug discovery platform Alphameldon April 29, 2021 at 4:15 pm
Shionogi & Co. Ltd. has inked a multitarget drug discovery collaboration for Inveniai LLC’s artificial intelligence and machine learning platform Alphameld. Inveniai is eligible to receive up to $200 ...
- Senior Research Associate - The Center for AI in Drug Discoveryon April 28, 2021 at 1:50 pm
Provide leadership to the development of presentations and publications related to research projects as the lead author. Participate in weekly group meetings and regularly meet collaborators from ...
- GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platformon April 28, 2021 at 9:54 am
GB Sciences (“GBS”), Inc. (OTCQB: GBLX), announced today that a provisional patent application has been filed to protect their proprietary drug discovery platform, which includes a data analytics ...
- InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaborationon April 27, 2021 at 5:24 am
and Machine Learning (ML) to transform innovation across drug discovery and development, today announced a multi-target drug discovery collaboration with Shionogi & Co., Ltd. (Head Office ...
- InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaborationon April 27, 2021 at 5:10 am
Teams will work together by leveraging InveniAI's technology to identify, evaluate, and optimize novel targets for drug discoveryShionogi will synthesize and develop compounds for targets identified ...
- Here’s a look at natural product drug discovery 2.0on April 26, 2021 at 2:33 pm
Plant-based drug discovery may be tens of thousands of years old, but in 2021, it feels exciting, rich, and full of potential. Companies are rapidly building scalable databases with hundreds of ...
- Genetics Unzipped podcast: Making better medicines – unlocking the promise of genomics for drug discoveryon April 22, 2021 at 7:06 am
In the latest episode of Genetics Unzipped, Kat Arney explores how researchers are using new technologies like CRISPR and AI to develop better drugs.
- ThinkCyte, Inc.: Machine vision-based cell sorting transforms cell therapy and drug discoveryon April 20, 2021 at 7:53 am
Applying machine-learning methods directly to the compressed waveforms—without time-consuming image reconstruction—enables real-time ‘image-free’ vision-based cell sorting 1.
- A one-stop shop for de novo drug discoveryon April 20, 2021 at 7:53 am
a drug discovery platform that helps pharmaceutical companies design new drug structures using artificial intelligence (AI) technologies, such as machine learning (Fig. 1). “The idea for Deep ...
via Google News and Bing News